$3.480
-0.116 (-3.33%)終値時点
ANIX のニュース
ANIX のイベント
Anixa Biosciences Secures New Patent in Australia
Anixa Biosciences announced that IP Australia has issued a Notice of Acceptance for a new patent related to Anixa's breast cancer vaccine technology. This patent, exclusively licensed from Cleveland Clinic, will provide protection for the company's novel approach to breast cancer treatment and prevention in Australia. The Australian patent complements patents issued in the U.S. and other key global jurisdictions, including Europe, China, and Japan, among others, and represents an important step toward potential future regulatory approvals and commercialization efforts outside the U.S. In a recently completed Phase 1 trial, at Cleveland Clinic and funded by the U.S. Department of Defense, the vaccine met all major primary endpoints, was safe and well tolerated, and generated protocol defined immune responses in more than 74% of participants.
Anixa Biosciences Treats First Patient in New Therapy Trial
Anixa Biosciences announced that the first patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T/CER-T therapy for recurrent ovarian cancer. The study is being conducted at Moffitt Cancer Center. As of the date of this release, five patients in the study have surpassed one year of survival following treatment, with individual patients surviving approximately 28, 20, 17, 17, and 13 months post-treatment, respectively. The Company believes these outcomes are notable in a highly pre-treated, recurrent ovarian cancer population that has progressed after multiple prior lines of therapy and limited treatment options and poor prognosis. Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, stated, "Advancing to the fifth cohort and highest dose level while observing no dose-limiting toxicities across the study to date is a meaningful milestone for the program. Ovarian cancer remains one of the deadliest cancers affecting women, and patients with recurrent disease face limited treatment options and poor outcomes. While this Phase 1 study is primarily designed to evaluate safety, we are highly encouraged that five patients have surpassed one year of survival following treatment, with one patient having survived beyond two years. ."
Anixa Biosciences Secures Patent for Breast Cancer Vaccine in South Korea
Anixa Biosciences announced that the Korean Ministry of Intellectual Property has issued Patent Number 10-2960889 related to Anixa's breast cancer vaccine technology. This composition-of-matter patent, exclusively licensed from Cleveland Clinic, protects the company's novel approach to breast cancer prevention and treatment in South Korea through 2040, addressing a disease for which no preventive vaccine is currently approved anywhere in the world.
Anixa Biosciences Presents Cancer Immunotherapy Progress at New York Symposium
Anixa Biosciences announced that its two clinical-stage immunotherapy programs were presented at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy symposium this week. The presentations highlighted Anixa's breast cancer vaccine, being developed in collaboration with Cleveland Clinic, which recently completed a Phase 1 clinical trial in which all major primary endpoints were met and protocol-defined immune responses were generated in 74% of participants, and Anixa's ovarian cancer CAR-T therapy, liraltagene autoleucel, or lira-cel, which is being evaluated in an ongoing Phase 1 clinical trial in collaboration with Moffitt Cancer Center. "Presenting both of our clinical-stage immunotherapy programs at this symposium was an important opportunity to highlight the progress of our pipeline and the strength of the collaborations supporting these programs," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "Our breast cancer vaccine and ovarian cancer CAR-T therapy are being advanced with leading clinical and scientific institutions, and we believe these presentations underscore the potential of Anixa's approach to treating and preventing cancer." The company's breast cancer vaccine presentation, titled "Phase I Trial of an Alpha-Lactalbumin Vaccine for Breast Cancer," was given by Dr. Emily Esakov Rhoades, FDA/IND Trial Program Manager, Cleveland Clinic Cancer Institute. The presentation reported final Phase 1 findings for the investigational vaccine, including that all major primary endpoints were met, the vaccine was safe and well tolerated at the maximum tolerated dose based on safety and tolerability, and protocol-defined immune responses were elicited in 74% of trial participants. The company's lira-cel presentation, titled "A Phase I Clinical Trial of an Infusion of Autologous T cells Genetically Engineered with a Chimeric Receptor to Target the Follicle-Stimulating Hormone Receptor in Patients with Recurrent Ovarian Cancer," was given by Dr. Pamela D. Garzone, Chief Development Officer of Anixa Biosciences. The presentation reported the clinical trial design and objectives, as well as the current status of Anixa's ongoing Phase 1 clinical trial of lira-cel, including survival observations of multiple patients living over one year past treatment.
Anixa Biosciences Secures Patent Allowance for Ovarian Cancer Vaccine
Anixa Biosciences announced that the Canadian Intellectual Property Office has issued a Notice of Allowance for a patent covering key aspects of Anixa's ovarian cancer vaccine technology. The allowed patent, exclusively licensed from Cleveland Clinic, includes methods of administering an immunogenic composition comprising a nucleic acid encoding the anti-Mullerian hormone receptor 2 polypeptide to elicit an AMHR2-specific immune response to prevent or treat ovarian cancer.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。